Our
Collaborations
Immatics harnesses a suite of technology platforms matched with advanced biologic understanding to identify antigens which are highly specific to cancer cells, thereby delivering true targets: distinct molecular barcodes that identify tumor cells and that are not present on healthy cells. The resulting target resource gives the Immatics team a drug discovery advantage for the company’s own proprietary pipeline and for collaborations with world-leading industry partners.
Immatics expects to grow utilizing the knowledge and experience gained from the partnered programs to improve the development pathways for its proprietary programs.
September 2023
Moderna – Research & Development Collaboration
Immatics and Moderna enter strategic research and development collaboration spanning various therapeutic modalities including bispecifics, cell therapy and cancer vaccines
June 2022
Editas Medicine – Research Collaboration
Immatics and Editas Medicine Enter Strategic Collaboration and Licensing Agreement to Combine Gamma Delta T Cell Adoptive Cell Therapies and Gene Editing
June 2022
Bristol Myers Squibb – Research collaboration
Immatics and Bristol Myers Squibb Enter Strategic Collaboration to Develop Off-the-shelf Allogeneic γδ-based TCR-T/ CAR-T Programs
August 2019
Bristol Myers Squibb – Research collaboration
Immatics and Bristol Myers Squibb Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
August 2015
MDACC – Strategic partnership
Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies